A REVIEW ON RECENT TRENDS IN NIOSOMAL ANTIGLAUCOMA DRUG DELIVERY SYSTEM

The chronic glaucoma with open angle is the second leading cause of blindness in the world. Ophthalmic drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical scientist. Poor bioavailability of drugs from ocular dosage form is mainly due to the tear production, non-productive absorption, transient residence time, and impermeability of corneal epithelium. Conventional preparations require frequent instillation, and long term use of such preparations and can cause ocular surface disorders. In recent years, significant efforts have been directed towards the development of new carrier systems for ocular drug delivery. Among these, non‐ionic surfactant vesicles i.e. niosomes could be a potential one for the effective treatment of glaucoma patients and have gained popularity in ocular drug delivery research. This article reviews the constraints of conventional ocular therapy, complications of glaucoma therapy, and newer advances in the field of anti‐glaucomatic niosomal formulation.